619 results on '"Okada, Annabelle A."'
Search Results
2. Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration
3. Three-month outcomes of faricimab loading therapy for wet age-related macular degeneration in Japan
4. TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2
5. INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN: A Multicenter Age-Related Macular Degeneration Study
6. Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
7. Evolving consensus for immunomodulatory therapy in non-infectious uveitis during the COVID-19 pandemic
8. One-year outcomes and safety assessment of faricimab in treatment-naïve patients with neovascular age-related macular degeneration in Japan
9. COVID-19 vaccination-related intraocular inflammation in Japanese patients
10. Clinical features and visual outcomes of ocular sarcoidosis at a tertiary referral center in Tokyo
11. Use of systemic corticosteroids in patients newly registered at a claims database with a diagnosis of non-infectious uveitis: results from a real-world claims database analysis
12. Short-term results for brolucizumab in treatment-naïve neovascular age-related macular degeneration: a Japanese multicenter study
13. Subfoveal choroidal thickness after brolucizumab therapy for neovascular age-related macular degeneration: a short-term multicenter study
14. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the ALTAIR Study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy Subgroup
15. Long-term changes of choroidal blood flow velocity in Vogt-Koyanagi-Harada disease
16. Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study
17. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
18. Correction to: Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial
19. Prevalence and incidence rates and treatment patterns of non-infectious uveitis in Japan: real-world data using a claims database
20. TENAYA and LUCERNE
21. Pachychoroid: current concepts on clinical features and pathogenesis
22. Anti-VEGF intravitreal injections in the era of COVID-19: responding to different levels of epidemic pressure
23. Correction to: Relationship between retinal fluid and visual acuity in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen: subgroup and post-hoc analyses from the ALTAIR study
24. Incidence and Risk factors of Intraocular Inflammation after Brolucizumab Treatment in Japan: A Multicenter AMD Study
25. Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
26. Management of retinal pigment epithelium tear during anti-VEGF therapy
27. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy
28. COVID Vaccine-Associated Uveitis
29. Posterior Uveitis
30. SUSPENDING TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN CASES OF FUTILITY
31. Ten-year follow-up of infliximab treatment for uveitis in Behçet disease patients: A multicenter retrospective study
32. Reply to Comment on: SUN Classification Criteria for Vogt-Koyanagi-Harada Disease
33. SUB-TENON TRIAMCINOLONE ACETONIDE INJECTION IN A PREGNANT PATIENT WITH VOGT–KOYANAGI–HARADA DISEASE
34. Short-Term Changes in Choroidal Thickness After Aflibercept Therapy for Neovascular Age-Related Macular Degeneration
35. Automated Quantitative Analysis of Anterior Segment Inflammation Using Swept-Source Anterior Segment Optical Coherence Tomography: A Pilot Study
36. COVID-19 vaccination-related intraocular inflammation in Japanese patients
37. Comparative Analysis of Serum microRNA in Diagnosed Ocular Sarcoidosis versus Idiopathic Uveitis with Ocular Manifestations of Sarcoidosis
38. Compromised blood flow of the optic nerve head in acute retinal necrosis
39. Prognostic value of subfoveal choroidal thickness in new‐onset acute Vogt‐Koyanagi‐Harada disease
40. A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine.
41. Dehydroxymethylepoxyquinomicin, a novel nuclear factor–κB inhibitor, reduces chemokines and adhesion molecule expression induced by IL-1β in human corneal fibroblasts
42. Development and validation of new diagnostic criteria for acute retinal necrosis
43. A COVID-19 Risk Reduction Strategy for the Treatment of Acute Vogt-Koyanagi-Harada Disease Utilizing the Antiviral Potential of Cyclosporine
44. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
45. Assessment of vision-related quality of life among patients with cataracts and the outcomes of cataract surgery using a newly developed visual function questionnaire: the VFQ-J11
46. Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in Exudative Age-Related Macular Degeneration: 52- and 96-Week Findings from ALTAIR
47. Spectral domain and swept source optical coherence tomography findings in acute retinal necrosis
48. MicroRNAs in retina during development of experimental autoimmune uveoretinitis in rats
49. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study
50. Frequency of Distinguishing Clinical Features in Vogt-Koyanagi-Harada Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.